All the Drug Class Drugs
Proteasome Inhibitor. Bortezomib 3.5 mg. VIAL (Pwdr. for sol. for IV/SC inj.): 1. Init. dose of Bortezomib is 1.3mg/m², may be admin. IV at a conc. of 1 mg/mL, or SC at a conc. of 2.5 mg/mL. When admin. IV, the drug is admin. as a 3-5 sec. bolus IV inj.
Because each route of admin. has a different reconstituted conc., caution should be used when calculat. the volume to be admin. This med. is for IV or SC use only, must not be admin. by any other route. Intrathecal admin. has resulted in death. Dose must be individualized. See lit.
Tmt. of pts. with multiple myeloma.
Tmt. of pts. with mantle cell lymphoma who have received at least one prior ther.
Bortezomib in comb. with rituximab, cyclophosphamide, doxorubicin and prednisone is indic. for the tmt. of adult pts. with prev. untreat. mantle cell lymphoma who are unsuitable for hematopoietic stem cell transplant.
C/I: Hypersens. (not include. local react.) to bortezomib, boron, or mannitol. React. have include. anaphyl. react.
Pts. with acute diffuse infiltrative pulmon. & pericard. dis. Intrathecal admin.
Proteasome Inhibitor. Bortezomib 3.5 mg. VIAL (pwdr. for sol. for inj. SC IV):1×3.5mg.
Initial. is 1.3 mg/m2. may be admin. IV at a concent. of 1 mg/mL, or SC at a concent. of 2.5 mg/mL. When admin. IV, Bortezomib is admin. as a 3 -5 second bolus IV inj. Not for intrathecal use. See lit.
Tmt. of pts. with multip.myeloma. Tmt. of pts. with mantle cell lymphoma who have received at least one prior ther. Bortezomib in comb. with rituximab, cyclophosphamide, doxorubicin and prednisone- tmt. of adult pts. with prev. untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplant.
C/I: Pts. with hypersens. (not includ. local react.), anaphylactic react. to bortezomib, boron, or mannitol. Pts. with acute diffuse infiltrative pulmon. and pericard. dis. Intrathecal admin. (due to fatal events).
Proteasome Inhibitor. Carfilzomib 60 mg/vial. SINGLE DOSE VIALS (lyophilized cake/ pwdr. for reconst.): 1×10,30,60 mg.
Monother.: IV as a 10-min. infus. In Cycles 1 through 12, admin. Carfilzomib on two consecut. d., each wk. for three wks. follow. by a 12-d. rest period. Each 28-d. period is consid. one tmt. cycle. From Cycle 13, omit the Day 8 and 9 doses of Carfilzomib. Premedicate with dexamethasone 4 mg oral. or IV 30 min. to 4 hrs. before each Carfilzomib dose in Cycle 1, then as needed to help prevent infus. reactions. The recomm. start. dose of Carfilzomib is 20 mg/m² in Cycle 1 on Days 1 and 2. If tolerated, escalate the dose to 27 mg/m² on Day 8 of Cycle 1. Tmt. may cont. until dis. progres. or unacceptab. toxicity occurs.
For comb. with Dexamethasone and comb. with Lenalidomide and Dexamethasone: See lit.
In comb. with dexamethasone or with lenalidomide plus dexamethasone for the tmt. of pts. with relapsed or refract. multiple myeloma who have received one to three prior lines of ther.
As a single agent for the tmt. of pts. with multiple myeloma who have received at least two prior therapies includ. bortezomib and an immunomodulat. agent and have demonstr. dis. progres. on or within 60 d. of completion of the last ther. Approval is based on response rate. Clinical benefit, such as improv. in survival or sympt., has not been verified.
Proteasome Inhibitor. Bortezomib 3.5 mg. VIAL (pwdr for sol.): 1. Initial: 1-3 mg/m2 2
x wkly for 2 wks (days 1, 4, 8, and 11)
foll. by 10 day rest period (days 12-21).
This 3 wk. period is a tmt. cycle. At
least 72 hrs. should elapse betw.
consec. doses. See lit.
Myeloma in pts. who have receiv. at least
two prior therapies and have shown
disease progress. on the last ther.
C/I: Hypersens., severe hepat. impair.